This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
*Eligible commercially insured patients can save up $1,500 per prescription. Maximum annual savings up to $1,500. Please click here for full terms and conditions for the PAXCESSTM Co-Pay Savings Program.
†The USG PAP operated by Pfizer is an independent program with separate eligibility requirements offered by the United States Department of Health and Human Services and is not owned by Pfizer. Please click here for the full terms and conditions of the USG PAP.
PAXLOVID is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID‑19, including hospitalization or death.2
Treat fast within 5 days of symptom onset even if baseline COVID-19 symptoms are mild.2
Many adults are living with at least 1 risk factor that puts them at high risk for progression to severe COVID-19 and may benefit from early treatment with PAXLOVID.3
Learn about the BOXED WARNING, contraindications, managing concomitant medications, and which medications to avoid when taking PAXLOVID.
Discover the safety data from the EPIC-HR trial.
Have a question about PAXLOVID?
Request a visit from a product representative.
Have a question about PAXLOVID?
Request a visit from a product representative.
Find the answers to the top questions asked by healthcare providers about
drug interactions, access, and more.
Many adults are living with at least 1 risk factor that puts them at high risk for progression to severe COVID-19 and may benefit from early treatment with PAXLOVID.3
Many adults are living with at least 1 risk factor that puts them at high risk for progression to severe COVID-19 and may benefit from early treatment with PAXLOVID.3
Many adults are living with at least 1 risk factor that puts them at high risk for progression to severe COVID-19 and may benefit from early treatment with PAXLOVID.3
Drugs that are strong CYP3A inducers: PAXLOVID cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently discontinued CYP3A inducer:
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
Limitations of Use
PAXLOVID is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.